1. Introduction {#sec1-1}
===============

*T-box* genes encode a family of transcriptional regulators that bind via a highly evolutionary conserved DNA-binding domain, the *T-box*, to cognate DNA elements (T-box-binding elements) in promoters to activate or repress target gene transcription in a variety of developmental contexts \[[@ref1][@ref2][@ref3]\]. To date, more than 20 different mammalian *T-box* genes have been identified, many of which have orthologs in various multicellular organisms.

The T-box genes exhibit diverse patterns of spatial and temporal expression in embryonic development. Developmental functions of the T-box genes range from the specification of the primary germ layers by genes to later roles in limb development \[[@ref4][@ref5][@ref6]\] and also include specification of cell identity during organogenesis in cardiac development \[[@ref7][@ref8][@ref9]\]. The biologically important roles of several members of this gene family were further emphasized by clinical studies demonstrating that mutations in T-box genes are associated with numerous disease states in humans and by the observation that T-box genes are amplified in a subset of cancers \[[@ref10][@ref11]\].

TBX5, a member of the T-box family, is critical for forelimb development and cardiogenesis \[[@ref1][@ref2][@ref12]\]. *TBX5* independently promotes cardiac chamber formation in vertebrates \[[@ref13]\]. Song et al \[[@ref14]\] and Qian et al \[[@ref15]\] also showed that four transcription factors, GATA binding protein 4 (GATA4), heart- and neural crest derivative-expressed protein 2, myocyte-specific enhancer factor 2C, and *TBX5*, are capable of reprogramming adult mouse fibroblasts into functional cardiac-like myocytes *in vitro* and *in vivo*, and that expression of these factors in noncardiomyocytes enhances the function of injured hearts following myocardial infarction. Haploinsufficiency of *TBX5* causes Holt---Oram syndrome, an autosomal dominant disorder characterized by upper limb malformations and cardiac septation defects. *TBX5* gene mutations have also been associated with atrial septal defect, ventricular septal defect, and atrio-ventricular (AV) block \[[@ref10][@ref16]\]. *TBX5* gene polymorphisms have been associated with genetic determinants of the PR interval, QRS duration, and development of atrial fibrillation in the general population \[[@ref17][@ref18]\]. Kim et al \[[@ref19]\] also observed that genetic polymorphisms in the *TBX5* gene are associated with the risk of metabolic syndrome. Herein, *TBX5* genotypes/haplotypes were analyzed in 597 Taiwanese individuals to further elucidate the role of the *TBX5* gene in metabolic and inflammatory profiles associated with *TBX5*-related pathologies.

2. Materials and Methods {#sec1-2}
========================

2.1. Study population {#sec2-1}
---------------------

After written informed consent was obtained, the study participants, who had no known history of major systemic or cardiovascular diseases, were recruited during routine health examinations. Exclusion criteria included cancer, current renal or liver disease, and a history of myocardial infarction, stroke, or transient ischemic attacks. In addition, patients taking diabetes mellitus and/or lipid-lowering drugs during the period of blood sample collection were excluded from the analysis because previous reports revealed that these agents affect inflammation marker expression or concentrations \[[@ref20][@ref21][@ref22]\]. A total of 597 study participants \[314 men with a mean age (± standard deviation) of 44.6 ± 10.1 years and 283 women with a mean age of 46.55 ± 9.9 years\] were enrolled in the study. The clinical and biometric features of the study group are summarized in [Table 1](#T1){ref-type="table"}. Obesity was defined as a body mass index of 25 kg/m^2^ or above, according to Asian criteria \[[@ref23]\]. Current smokers were defined as individuals who smoked cigarettes regularly at the time of survey. The Ethics Committee of Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, approved the investigation.

###### 

Clinical and biochemical characteristics of the study participants stratified by gender.

                              Total            Men              Women            *p*
  --------------------------- ---------------- ---------------- ---------------- ---------
  No.                         597              314              283              
  Age (y)                     45.5 ± 10.1      44.6 ± 10.1      46.5 ± 9.9       0.018
  Body mass index (kg/m^2^)   24.3 ± 3.5       25.0 ± 3.2       23.6 ± 3.7       \<0.001
  Current smoker (%)          19.4             33.4             3.9              \<0.001
  CRP (mg/L)                  1.6 ± 6.1        1.9 ± 7.9        1.4 ± 3.1        0.065
  Fibrinogen (μmol/L)         264.0 ± 69.6     261.8 ± 71.5     266.4 ± 67.5     0.414
  SELE (μg/L)                 53.5 ± 26.6      60.7 ± 28.4      45.5 ± 21.9      \<0.001
  SELP (ng/mL)                140.3 ± 116.9    155.4 ± 131.6    123.6 ± 95.7     \<0.001
  SAA (μmol/L)                6.2 ± 15.6       7.2 ± 19.8       5.1 ± 9.0        0.240
  sICAM1 (μg/L)               241.8 ± 112.3    245.5 ± 111.9    237.5 ± 112.8    0.435
  sVCAM1 (μg/L)               491.5 ± 132.4    495.8 ± 149.9    486.8 ± 109.9    0.504
  MMP1 (pg/mL)                459.4 ± 1136.2   338.3 ± 549.8    593.3 ± 1534.7   0.747
  MMP2 (ng/mL)                126.8 ± 41.0     123.7 ± 41.6     130.2 ± 40.0     0.016
  MMP9 (ng/mL)                144.0 ± 112.45   155.8 ± 116.3    130.8 ± 106.7    \<0.001
  sTNFRII (pg/mL)             3269.3 ± 948.3   3338.9 ± 996.8   3192.2 ± 887.0   0.061

Continuous variables are presented as mean ± standard deviation. SAA, CRP, sICAM1, sVCAM1, SELE, SELP, MMP1, and MMP9 values were transformed logarithmically before statistical testing to meet the assumption of normal distributions; however, untransformed data are shown.

CRP= C-reactive protein; MMP = matrix metalloproteinase; SAA = serum amyloid A; SD = standard deviation; SELE = soluble E-selectin; SELP = soluble P-selectin; sICAM1 = soluble intercellular adhesive molecule 1; sVCAM1 = soluble vascular cell adhesive molecule 1; sTNFRII = soluble tumor necrosis factor receptor II.

2.2. Laboratory examination {#sec2-2}
---------------------------

Prior to starting the study, all participants underwent an initial screening assessment that included medical history, vital signs, and measurement of lipid variables and novel risk factors. A total of 15 mL of venous blood was collected in the morning after an overnight (8---12-hour) fast. Venous blood samples were collected from an antecubital vein with a 21-gauge needle. Serum, EDTA, sodium fluoride, and sodium citrate plasma samples were obtained by centrifugation at 3000g for 15 minutes at 4°C. Immediately after centrifugation, serum/plasma samples were frozen and stored at --80° C prior to analysis. All measurements were performed in a central laboratory.

2.3. Assays {#sec2-3}
-----------

Most markers, including serum C-reactive protein, serum amyloid A, soluble intercellular adhesive molecule 1, soluble vascular cell adhesive molecule 1, soluble E-selectin (SELE), matrix metal-loproteinase (MMP) 2, and MMP9 were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) developed in house. All in-house kits showed good correlation when compared with commercially available ELISA kits \[[@ref24][@ref25][@ref26]\]. Circulating plasma MMP1, soluble P-selectin, and soluble tumor necrosis factor receptor II were measured using commercially available ELISA kits from R&D (Minneapolis, MN, USA).

2.4. Genomic DNA extraction and genotyping {#sec2-4}
------------------------------------------

Genomic DNA was extracted as previously reported \[[@ref27][@ref28]\]. From the published sequence of the *TBX5* gene, oligonucleotide primers were generated to amplify fragments of genomic DNA containing genetic polymorphisms reported on the National Center for Biotechnology Information single nucleotide polymorphism (SNP) database (<http://www.ncbi.nlm.nih.gov/SNP>). Based on the HapMap database, five tag SNPs were chosen, which covered a haplotype region with an *R*^2^ = 0.85 and minor allele frequency of \> 0.4 ([Table 2](#T2){ref-type="table"}). Genotyping for SNPs rs1247973, rs4113925, and rs3825214 was performed using polymerase chain reaction and restriction enzyme digestion. Genotyping for SNPs rs11067101and rs2236017 was performed using TaqMan SNP genotyping assays obtained from Applied Biosystems (Foster City, CA, USA).

###### 

Primer sequences and RE used in *TBX5* polymorphisms.

  SNP No.      Primer sequence                         PCR size and RE   Allele   Location   Hardy---Weinberg *p*
  ------------ --------------------------------------- ----------------- -------- ---------- ----------------------
  rs11067101   TaqMan SNP genotyping assays                              A/G      Intron 1   1
  rs2236017    TaqMan SNP genotyping assays                              T/G      Intron 6   0.743
  rs1247973    (F)5'-TATACCTTCCAGCATAACTCGG-3'         316 bp            C/T      Intron 7   0.989
               (R)5'-TTGACACATATTAGGGGGACAC-3'         Nal III                               
  rs4113925    (F)5'-CACTCCAGCCTGGGCAACAAGA-3'         271 bp            A/G      Intron 7   0.895
               (R)5'-GCAAGTCAAACCTGGCATCTGGC-3'        Sal I                                 
  rs3825214    (F)5'-ATTTGAATCAGGCTCCTTTACTTAATAT-3'   227 bp            A/G      Intron 8   0.917
               (R)5'-TATTATTGTGAATTATGTCTGCCATAAG-3    Hind III                              

PCR = polymerase chain reaction; RE = restriction enzyme; SNP = single nucleotide polymorphism.

2.5. Statistical analysis {#sec2-5}
-------------------------

The Chi-square test was used for comparisons of the categorical variables of smoking. Clinical characteristics as continuous variables were expressed as means ± standard deviation, and tested by two-sample *t* test or analysis of variance. A generalized linear model was used to analyze MMP9 levels in relation to predictors of the investigated genotypes and confounders. Data on C-reactive protein, serum amyloid A, soluble intercellular adhesive molecule 1, soluble vascular cell adhesive molecule 1, SELE, soluble P-selectin, MMP1, MMP2, MMP9, and soluble tumor necrosis factor receptor II were logarithmically transformed prior to statistical analysis to adhere to a normality assumption. A value of *p* \< 0.05, using two-sided tests, was considered statistically significant.

Interactions between each SNP, MMP9 level, and obesity status were tested using two-way analysis of variance. When interaction terms were significant, stratified analyses of the genetic variants of the genotypes (e.g., target genotypes affected by obesity) and MMP9 levels were performed to further investigate interactive effects while controlling for other variables including age, gender, and smoking. The analysis of deviation from the Hardy---Weinberg equilibrium, estimation of linkage disequilibrium between polymorphisms, association between haplotypes and MMP9 levels, and haplotype---obesity interactions were performed using the Golden Helix SVS Win32 7.3.1 software (Golden Helix, Bozeman, MT, USA).

3. Results {#sec1-3}
==========

3.1. Clinical and biochemical characteristics {#sec2-6}
---------------------------------------------

A summary of the characteristics, clinical profiles, and inflammatory biomarkers of the study participants (stratified by gender) is provided in [Table 1](#T1){ref-type="table"}. No significant deviation from the Hardy---Weinberg equilibrium was detected for the studied polymorphisms (*p* = 1.00, *p* = 0.743, *p* = 0.989, *p* = 0.895, and *p* = 0.917 for SNPs rs11067101, rs2236017, rs1247973, rs4113925, and rs3825214, respectively; [Table 2](#T2){ref-type="table"}). Two pairs of SNPs, rs2236017 and rs1247973 as well as rs3825214 and rs4113925, showed strong pairwise linkage disequilibrium ([Table 3](#T3){ref-type="table"}).

###### 

Linkage disequilibrium between *TBX5* genetic polymorphisms.^a^

               rs2236017   rs1247973   rs4113925   rs3825214
  ------------ ----------- ----------- ----------- -----------
  rs11067101   0.056170    0.19214     0.005501    0.004083
  rs2236017    ---         0.905577    0.421236    0.407054
  rs1247973    ---         ---         0.019257    0.050587
  rs4113925    ---         ---         ---         0.798946

^a^ The values represent D'.

3.2. Associations between TBX5 gene polymorphisms and circulating MMP9 levels {#sec2-7}
-----------------------------------------------------------------------------

To determine whether the *TBX5* genotypes affected circulating inflammatory marker levels, 11 inflammatory markers were analyzed, including C-reactive protein, fibrinogen, serum amyloid A, soluble intercellular adhesive molecule 1, soluble vascular cell adhesive molecule 1, SELE, soluble P-selectin, soluble tumor necrosis factor receptor II, MMP1, MMP2, and MMP9. Our results showed that genetic variants in or around the *TBX5* gene were significantly associated with MMP9 levels in Taiwanese individuals ([Table 4](#T4){ref-type="table"}). After adjusting for clinical covariates, significant associations with the MMP9 level were observed for two polymorphisms, rs4113925 and rs3825214, using an additive inheritance model (*p* = 0.013 and *p* = 0.019, respectively). In the dominant model, minor alleles of rs4113925 and rs3825214 were associated with a higher MMP9 level (*p* = 0.002 and *p* = 0.001, respectively).

###### 

Associations between *TBX5* genotypes and MMP9 levels.

  *TBX5* genotypes             MMP9 levels             *p*^a^
  ------------------ --------- ----------------------- --------
  rs11067101         AA        143.79 ± 117.19(112)    0.255
                     AG        137.21 ± 110.52 (283)   
                     GG        155.93 ± 114.72 (176)   
                     AA + AG   139.08 ± 112.34(395)    0.073
                     GG        155.93 ± 114.72 (176)   
  rs2236017          TT        155.69 ± 128.78 (54)    0.728
                     TG        140.87 ± 116.82 (257)   
                     GG        147.69 ± 107.70 (249)   
                     TT + TG   143.45 ± 118.90(311)    0.376
                     GG        147.69 ± 107.70 (249)   
  rs1247973          CC        161.14± 141.38 (130)    0.204
                     CT        138.10 ± 98.91 (286)    
                     TT        141.49 ± 110.44(156)    
                     CC + CT   145.30 ± 114.22 (416)   0.846
                     TT        141.49 ± 110.44(156)    
  rs4113925          AA        124.02 ± 96.12 (175)    0.013
                     AG        153.55 ± 119.56 (276)   
                     GG        152.36 ± 117.79(121)    
                     AA        124.02 ± 96.12 (175)    0.002
                     AG + GG   153.18 ± 118.87 (397)   
  rs3825214          GG        147.61 ± 101.70 (94)    0.019
                     GA        159.35± 129.01 (266)    
                     AA        124.61 ± 92.38 (209)    
                     GG + GA   156.28 ± 122.44 (360)   0.001
                     AA        124.61 ± 92.38 (209)    

Data are presented as mean ± standard deviation (*N*).

MMP9 = matrix metalloproteinase 9; *N* = number of subjects; SD = standard deviation.

^a^ The *p* value is adjusted for age, sex, body mass index, and smoking status.

3.3. TBX5 haplotypes and MMP9 levels {#sec2-8}
------------------------------------

As SNP regression demonstrated that multiple sites within the *TBX5* gene significantly affected MMP9 levels, haplotypes were inferred to capture possible allelic associations. In the present investigation, two pairs of SNPs, rs2236017 and rs1247973 as well as rs3825214 and rs4113925, showed strong pairwise linkage disequilibrium; thus, three tag SNPs (rs11067101, rs12479730, and rs3825214) were enrolled for haplotype analysis. Eight common haplotypes (≥ 5% frequency) were derived from these three SNPs, accounting for all inferred haplotypes. Haplotype analysis revealed a significant association between the *TBX5* haplotype GCG and MMP9 levels (uncorrected *p* = 0.0093 and corrected false discovery rate *p* = 0.0435) ([Table 5](#T5){ref-type="table"}).

###### 

Associations between TBX5 locus haplotypes and MMP9 levels.^a^

       Haplotype   Frequency (%)   MMP9 level   *p*2     
  ---- ----------- --------------- ------------ -------- --------
  H1   GCA         19.3            --0.0970     0.4078   0.6493
  H2   ATA         17.9            --0.0291     0.0184   0.0720
  H3   GTA         14.3            0.0145       0.7880   0.8589
  H4   GCG         11.5            --0.0669     0.0093   0.0435
  H5   GTG         10.8            --0.2063     0.1882   0.4298
  H6   ATG         9.3             0.0495       0.7609   0.8447
  H7   ACA         8.5             0.0575       0.6541   0.8244
  H8   ACG         8.4             0.0886       0.1816   0.4395

MMP9 = matrix metalloproteinase 9; *p*1 = uncorrected *p* value; *p*2 = corrected false discovery rate *p* value; SNP = single nucleotide polymorphisms.

^a^ SNP1, rs11067101; SNP2, rs1247973; SNP3, rs3825214. Coefficients and *p* values were estimated based on haplotype trend regression analysis implemented in the HelixTree program. The selected haplotype was compared to all unselected haplotypes, adjusted for age, sex, smoking, and body mass index.

3.4. Stepwise regression analysis of MMP9 levels using a general linear model in the study population {#sec2-9}
-----------------------------------------------------------------------------------------------------

In addition to the independent variables associated with MMP9 levels, as reported previously by Wu et al \[[@ref29]\], *TBX5* gene variants, gender, and body mass index were further used for multivariate analysis. In a stepwise regression analysis, the *TBX5* SNP rs3825214 genotype with a dominant model, in addition to age, gender, smoking status, fibrinogen levels, and SELE SNP rs5368, was independently associated with MMP9 levels (*p* \< 0.05; [Table 6](#T6){ref-type="table"}).

###### 

MMP9 levels: stepwise linear regression analysis, including genotype.

  Variable                       Beta      *R*^2a^   *p*
  ------------------------------ --------- --------- ---------
  Gender                         -0.051    0.022     0.022
  Age                            -0.003    0.001     0.001
  BMI                            \<0.001   0.003     0.939
  Current smoker                 0.087     0.028     0.002
  Fibrinogen                     0.001     \<0.001   \<0.001
  Glucose                        0.001     \<0.001   0.056
  *SELE* rs5368 TT genotype      -0.155    0.044     \<0.001
  *MMP9* rs2274756 AA genotype   0.161     0.082     0.049
  *TBX5* rs3825214 AA genotype   -0.061    0.021     0.004

BMI = body mass index; MMP9 = matrix metalloproteinase 9; SELE = soluble E-selectin.

^a^ Cumulative *R*^2^. Multiple linear regression, adjusted for age, gender, smoking status, BMI, fibrinogen, fasting plasma glucose, *SELE* rs5368 genotype, *MMP9* rs2274756 genotype, and *TBX5* rs3825214 genotype.

3.5. Interactions between TBX5 genotypes/haplotypes, obesity, and MMP9 levels {#sec2-10}
-----------------------------------------------------------------------------

After adjusting for age, gender, and smoking status, subgroup and interaction analyses revealed associations between rs4113925, rs3825214, and MMP9 levels only in nonobese individuals, using a dominant inheritance model (*p* = 1.04 × 10^−4^ and *p* = 7.11 × 10^−5^, respectively; interaction *p* = 0.0088 and interaction *p* = 0.0183, respectively; [Fig. 1](#F1){ref-type="fig"}).

![Interactive effect of MMP9 levels on the association between *TBX5* genotypes and obesity status. (A) After adjusting for clinical covariates, the major allele of rs4113925 of the *TBX5* gene was found to be associated with decreased MMP9 levels in nonobese individuals (*p* = 1.04 × 10^−4^). Interaction analysis revealed an interaction between obesity status and the rs4113925 genotype (interaction *p* = 0.0088 for the dominant model, after adjustment for age, gender, and smoking status). (B) After adjusting for clinical covariates, the major allele of rs3825214 of the *TBX5* gene was found to be associated with decreased MMP9 levels in nonobese individuals (*p* = 7.11 × 10^−5^). Interaction analysis revealed an interaction between obesity status and the rs4113925 genotype (interaction *p* = 0.0183 for the dominant model, after adjustment for age, gender, and smoking status). MMP9 = matrix metalloproteinase 9.](TCMJ-28-9-g001){#F1}

Subgroup analysis showed a borderline significant association between the haplotype GCG and MMP9 levels (uncorrected *p* = 0.020 and corrected false discovery rate *p* = 0.073), but with no evidence of interaction (interaction *p* = 0.409) (data not shown).

4. Discussion {#sec1-4}
=============

This investigation analyzed the association between *TBX5* gene variants and metabolic profiles and inflammatory marker levels in Taiwanese individuals. Our data revealed significant associations between *TBX5* genotypes/haplotypes and MMP9 levels. The association with MMP9 levels is independent of our previously reported MMP9 and SELE gene variants. Interactions between obesity, *TBX5* genetic variants, and MMP9 levels were also noted. These data provide the first evidence that *TBX5* is a transcriptional regulator that may modulate the expression of MMP9. These results also expand our understanding of the underlying mechanism of the association between *TBX5* and cardiovascular diseases.

TBX5 is a transcriptional regulator in which mutations result in various congenital heart diseases. Heart formation requires a highly balanced network of transcriptional gene activation. *TBX5* also plays an important role in postnatal maturation of the AV node, AV bundle, and left and right bundle branch patterning \[[@ref30]\]. However, there is no *TBX5* binding site on the *MMP9* promoter region; thus, it is unlikely that *TBX5* alone directly regulates the expression of MMP9. *TBX5* commonly functions with other transcription factors, including NK2 transcription factor-related locus (NKX2-5). In a previous investigation, Hiroi et al \[[@ref31]\] revealed that two different types of cardiac transcriptional factors, *TBX5* and NKX2-5, directly bound to the promoter of the gene for cardiac-specific natriuretic peptide precursor type A *(NPPA)* in tandem, and both showed synergistic activation that induced cardiac development. *TBX5* also acts cooperatively with NKX2-5 to regulate the expression of short stature homeobox 2 and bone morphogenetic protein 4, which are essential for the formation of the pacemaker region of the developing heart \[[@ref32]\]. Co-occupancy of a chromatin region by multiple transcription factors has also been shown to identify a distinct set of developmentally relevant enhancers, including GATA4, NKX2-5, *TBX5*, serum response factor, and myocyte-enhancer factor 2A \[[@ref33]\]. An NKX2-5-binding site was identified on the *MMP9* promoter region by *in silico* analysis (<http://mbs.cbrc.jp/research/db/TFSEARCH>). Thus, it is possible that *TBX5* may act with NKX2-5 to regulate the expression of MMP9. Munshi et al \[[@ref34]\] demonstrated that a distal enhancer for connexin 30.2, a gap junction protein required for normal AV delay in mice, is necessary and sufficient to direct expression to the developing AV conduction system. This enhancer requires *TBX5* and GATA4 for proper expression in the conduction system. These results suggest the importance of *TBX5* in association with other transcription factors in regulating transcription and cardiac development.

Several lines of evidence suggest that MMP9 may be associated with some *TBX5*-related pathologies. Both *TBX5* and MMP9 have been associated with atrial and AV conduction pathologies with active fibrotic processes. Progressive cardiac conduction disease (PCCD), the most common cause of acquired, permanent, third- degree AV block, is characterized by a slow, progressive loss of AV conduction fibers. Increased myocardial collagen turnover with increased plasma MMP9 levels was observed in patients with PCCD \[[@ref35]\]. Cardiac remodeling induced by MMP9 appears to play a role in the pathomechanism of AV conduction delay and ventricular dilatation in hyperhomocysteinemia \[[@ref36]\]. Polymorphisms of the *TBX5* gene have also been associated with genetic determinants of the PR interval and QRS duration, markers of cardiac conduction. Atrial fibrosis in atrial fibrillation is characterized by severe alterations in collagen I and III synthesis/degradation associated with disturbed MMP/tissue inhibitor of metalloproteinase systems \[[@ref37]\]. Tumor necrosis factor triggers expression and activation of MMPs, including MMP9, contributing to adverse myocardial remodeling in atrial fibrillation \[[@ref38]\]. A higher risk of atrial fibrillation was also noted with *TBX5* gene variants \[[@ref17][@ref18]\]. Thus, it is possible that *TBX5* polymorphisms may act through MMP9, which results in *TBX5*- related pathologies.

The possibility that MMP9 is an intermediate between *TBX5* and cardiovascular pathologies is further supported by the study of TBX20, a closely related T-box family member of *TBX5*. Both *TBX5* and TBX20 are crucial lineage decisive players in early myocardial dichotomy with specification of chamber and nonchamber myocardium in the forming vertebral heart \[[@ref39]\]. *TBX20* mutations also contribute to various congenital heart diseases in Chinese patients, including atrial septal defect, total anomaly of pulmonary venous return, and tetralogy of Fallot \[[@ref40]\]. Similar to *TBX5*, cardiac TBX20 has been shown to directly interact with NKX2-5, GATA4, and GATA5 in the regulation of gene expression in the developing heart \[[@ref13]\]. More importantly, TBX20 has been shown to increase MMP9 and MMP13 expression in primary avian endocardial cells, which suggests an important role in extracellular matrix remodeling and promoting cell proliferation in mesenchymal valve precursor populations in the endocardial cushion during embryonic development \[[@ref41]\]. It is interesting that our data showed a significant association between *TBX5* gene polymorphisms and MMP9 levels in Taiwanese individuals. Further study is necessary to elucidate the role of the *TBX20* gene in regulating MMP9 levels.

Interactions between genotypes/adiposity and lipid variables/inflammatory markers have been demonstrated previously \[[@ref27][@ref29][@ref42][@ref43]\]. The present data provide further evidence that the interaction between obesity and *TBX5* genotypes/haplotypes affects MMP9 levels. Although there is no association between the MMP9 level and obesity, it is likely that an increased inflammatory status with adiposity may affect the role of genetic effects. Our data suggested that the genetic background associated with MMP9 levels might differ between obese and nonobese individuals.

Major limitations of the study include the use of a single population with a modest sample size and the cross-sectional design. Replication in a second cohort with a larger sample size and prospective design would improve the strength of the genetic association and interaction analyses. When the false discovery rate was applied for multiple tests in haplotype analysis, the statistical significance of a portion of our results became marginal. However, a significant *p* value was obtained in the multivariate analysis, suggesting that the association between the *TBX5* polymorphisms and MMP9 levels may not be due to chance.

In conclusion, the significant associations between *TBX5* genotypes/haplotypes and MMP9 levels observed in this investigation suggest that MMP9 is involved in *TBX5*-related pathology. Our results provide an insight into the regulation and functional mechanism underlying cardiac development and PCCD. The regulation of *TBX5*-induced MMP9 expression might represent a new therapeutic target for PCCD.
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